首页> 美国卫生研究院文献>Journal of Translational Medicine >Therapeutic properties of a vector carrying the HSV thymidine kinase and GM-CSF genes and delivered as a complex with a cationic copolymer
【2h】

Therapeutic properties of a vector carrying the HSV thymidine kinase and GM-CSF genes and delivered as a complex with a cationic copolymer

机译:带有HSV胸苷激酶和GM-CSF基因并与阳离子共聚物复合的载体的治疗特性

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BackgroundGene-directed enzyme prodrug therapy (GDEPT) represents a technology to improve drug selectivity for cancer cells. It consists of delivery into tumor cells of a suicide gene responsible for in situ conversion of a prodrug into cytotoxic metabolites. Major limitations of GDEPT that hinder its clinical application include inefficient delivery into cancer cells and poor prodrug activation by suicide enzymes. We tried to overcome these constraints through a combination of suicide gene therapy with immunomodulating therapy. Viral vectors dominate in present-day GDEPT clinical trials due to efficient transfection and production of therapeutic genes. However, safety concerns associated with severe immune and inflammatory responses as well as high cost of the production of therapeutic viruses can limit therapeutic use of virus-based therapeutics. We tried to overcome this problem by using a simple nonviral delivery system.
机译:背景技术基因导向的酶前药疗法(GDEPT)代表了一种提高对癌细胞的药物选择性的技术。它包括负责将前药原位转化为细胞毒性代谢物的自杀基因传递到肿瘤细胞中。阻碍其临床应用的GDEPT的主要局限性包括不能有效地递送到癌细胞中以及自杀酶对前药的活化不良。我们试图通过自杀基因疗法与免疫调节疗法的结合来克服这些限制。由于有效转染和产生治疗性基因,病毒载体在当今的GDEPT临床试验中占主导地位。然而,与严重的免疫和炎性反应以及生产治疗性病毒的高成本相关的安全性考虑会限制基于病毒的治疗剂的治疗用途。我们试图通过使用简单的非病毒递送系统来克服此问题。

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号